BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Hosted on MSN1mon
PRAX stock soars to 52-week high, hits $90.33 amid robust gainsP raxis Precision Medicines Inc. stock has reached a new 52-week high, with shares climbing to $90.33. According to InvestingPro data, the company's market capitalization now stands at $1.7 ...
Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor ...
Wall Street expects a year-over-year increase in earnings on lower revenues when Praxis Precision Medicines, Inc. (PRAX) reports results for the quarter ended December 2024. While this widely ...
NASDAQ PRAX opened at $37.12 on Thursday. Praxis Precision Medicines has a 12 month low of $30.01 and a 12 month high of $91.83. The firm has a market capitalization of $748.45 million, a PE ratio ...
Below is a chart showing DRI's trailing twelve month trading history, with the $180 strike highlighted in orange: And Praxis Precision Medicines Inc (Symbol: PRAX) saw options trading volume of ...
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback